Multi-cancer blood test Galleri fails NHS trial

What happened

A large trial in the UK’s National Health Service tested the multi-cancer blood test known as Galleri among 142,000 NHS patients. Results presented at an oncology conference in Chicago found that the test did not meet the trial’s main goal: reducing diagnoses of late-stage cancer.

Why it matters

The findings are important because multi-cancer detection tests are often evaluated based on whether they actually shift outcomes earlier enough to improve survival—not merely whether they detect cancer.

In this case, the trial’s primary endpoint was focused on downstream clinical impact: whether using the blood test leads to fewer cases being diagnosed at a late stage. When a study fails to show that effect, it raises questions about the benefit of population-level screening using that tool.

What the trial suggests

Based on the coverage provided, the key signal is that the test did not achieve the intended public-health impact in this NHS setting. That matters for health-system decisions about adoption, funding, and how to balance the promise of broad cancer detection against the evidence needed for real-world outcomes.

The core takeaway

The NHS study adds high-signal evidence that Galleri did not deliver the expected benefit in preventing late-stage cancer diagnoses, making policymakers and clinicians likely to scrutinize multi-cancer screening tests more closely before wider implementation.